Information is solely for medical professionals
Unit-dose Beifushu Eye Drops
Unit-dose b-bFGF Eye Drops
/
1680IU/0.4ml ; 0.4ml X 10/box
Unit-dose Befushu eye drops is a genetically engineered new drug developed and manufactured by Zhuhai Essex Bio-Pharmaceutical Co., Ltd.. As the third generation of Beifushu Series, it is a preservative-free formulation potentially delivering best treatment outcomes to patients.
Mechanism
The API of Beifushu is recombinant bovine basic fibroblast growth factor ( rb-bFGF ), which can stimulate the reparation and regeneration of tissues derived from the mesoderm and ectoderm. The specific combination of rb-bFGF with the wounded ocular surface(including corneal epithelial cells, endothelial cell and stromal cells) can trigger tissue repair activley by promting cell division, proliferation, migration and differentiation, so as to accelerate the healing of corneal wounds and improve the healing quality of cornea.
Features
· Protect cornea and promote the regeneration of cornea
· Accelerate the healing
· Shortening the healing time
· Repair cornea and accelerate the restoration of cornea function
· Safe and effective treatment without any side effect
· Preservative-free formulation
· Accelerate the healing
· Shortening the healing time
· Repair cornea and accelerate the restoration of cornea function
· Safe and effective treatment without any side effect
· Preservative-free formulation
Clinical Application
· Various corneal defects and punctate keratopathy
· Recurrent punctate keratopathy in the shallow layer
· Mild or moderate dry eye
· Corneal operation and poor corneal healing after surgery
· Geographic (or nutritional) herpes simplex keratitis
· Ballous keratitis
· Corneal abrasion, mild and moderate chemical burns
· Recurrent punctate keratopathy in the shallow layer
· Mild or moderate dry eye
· Corneal operation and poor corneal healing after surgery
· Geographic (or nutritional) herpes simplex keratitis
· Ballous keratitis
· Corneal abrasion, mild and moderate chemical burns
NDRL
《National Drug List for Basic Medical Insurance, Work Related Injury Insurance and Maternity Insurance (2023)》
Medical Guidelines
· Chinese Expert Consensus on Dry Eye Management, 2020
· Expert Consensus of Clinical Diagnosis and Treatment of Corneal Epithelial Lesions in China, 2016
· Expert Consensus of Clinical Diagnosis and Treatment of Laser Corneal Refractive Surgery, 2015
· Expert Consensus of Clinical Diagnosis and Treatment of Corneal Epithelial Lesions in China, 2016
· Expert Consensus of Clinical Diagnosis and Treatment of Laser Corneal Refractive Surgery, 2015
粵公網安備 44049102496184號